Tovecimig Plus FOLFIRI in Second Line Metastatic Colorectal Cancer
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorWashington University School of Medicine
About this trial
This is an open-label Phase 2 study to evaluate the safety and efficacy of Tovecimig combined with FOLFIRI in patients who have received one prior line of therapy for advanced or metastatic colorectal cancer (CRC).
Eligibility criteria
Qualifiers
Histologically or cytologically confirmed CRC.
Patient must have undergone resection of his/her primary tumor either as part of treatment for early stage disease with subsequent metastatic progression or due to a tumor related complication in the metastatic setting (e.g. bowel obstruction).
Measurable disease per RECIST 1.1.
Patient must have advanced or metastatic disease, and have progressed on one line of standard of care therapy in the advanced/metastatic setting
Disqualifiers
Patients with MSI-H status.
Intact primary tumor that has not been resected.
More than one line of prior therapy for advanced or metastatic CRC.
Surgery or major procedure, or systemic anticancer therapy within 4 weeks prior to C1D1.
Trial design
Treatments tested in this trial
- Tovecimig
- Irinotecan
- Leucovorin
- 5-Fluorouracil (5-FU)
Treatment groups
25 Participants
are divided into 1 treatment groupSponsors and collaborators
Washington University School of Medicine
Lead sponsor
Compass Therapeutics
Collaborator
Source ClinicalTrials.gov